These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23326338)

  • 1. Leuprorelin acetate long-lasting effects on GnRH receptors of prostate cancer cells: an atomic force microscopy study of agonist/receptor interaction.
    Lama G; Papi M; Angelucci C; Maulucci G; Sica G; De Spirito M
    PLoS One; 2013; 8(1):e52530. PubMed ID: 23326338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors.
    Angelucci C; Lama G; Iacopino F; Ferracuti S; Bono AV; Millar RP; Sica G
    Endocrine; 2009 Aug; 36(1):87-97. PubMed ID: 19399647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
    Angelucci C; Iacopino F; Lama G; Capucci S; Zelano G; Boca M; Pistilli A; Sica G
    Anticancer Res; 2004; 24(5A):2729-38. PubMed ID: 15517879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoperone IN3 enhances the apoptotic effect of leuprolide in prostate cancer cells by increasing the gonadotropin-releasing hormone receptor in the cell membrane.
    Sánchez CA; Mercado AJ; Contreras HR; Cabezas JC; Huidobro CC; Castellón EA
    Anticancer Drugs; 2012 Oct; 23(9):959-69. PubMed ID: 22713594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
    Britten JL; Malik M; Levy G; Mendoza M; Catherino WH
    Fertil Steril; 2012 Nov; 98(5):1299-307. PubMed ID: 22901846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
    Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
    Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
    Iacopino F; Lama G; Angelucci C; Sica G
    Int J Oncol; 2006 Jul; 29(1):237-47. PubMed ID: 16773205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma.
    Sánchez C; Clementi M; Benitez D; Contreras H; Huidobro C; Castellón E
    Prostate; 2005 Nov; 65(3):195-202. PubMed ID: 15948150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leuprorelin acetate affects adhesion molecule expression in human prostate cancer cells.
    Angelucci C; Lama G; Iacopino F; Sica G
    Int J Oncol; 2011 Jun; 38(6):1501-9. PubMed ID: 21479359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system.
    Dondi D; Festuccia C; Piccolella M; Bologna M; Motta M
    Oncol Rep; 2006 Feb; 15(2):393-400. PubMed ID: 16391860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145.
    Ko YH; Ha YR; Kim JW; Kang SG; Jang HA; Kang SH; Park HS; Cheon J
    J Int Med Res; 2011; 39(3):729-39. PubMed ID: 21819703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
    Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
    Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of mRNA expression of gonadotropin-releasing hormone and its receptor in normal and neoplastic rat prostates.
    Lau HL; Zhu XM; Leung PC; Chan LW; Chen GF; Chan PS; Yu KL; Chan FL
    Int J Oncol; 2001 Dec; 19(6):1193-201. PubMed ID: 11713589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism responsible for the supraphysiologic gonadotropin surge in females treated with gonadotropin-releasing hormone (GnRH) agonist and primed with GnRH antagonist.
    Taylor JE; Miller BT; Gray KD; Scott RT; Catherino WH; Segars JH
    Fertil Steril; 2010 Mar; 93(5):1668-75. PubMed ID: 19200975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer.
    Katsila T; Balafas E; Liapakis G; Limonta P; Montagnani Marelli M; Gkountelias K; Tselios T; Kostomitsopoulos N; Matsoukas J; Tamvakopoulos C
    J Pharmacol Exp Ther; 2011 Mar; 336(3):613-23. PubMed ID: 21106905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone receptor concentration differentially regulates intracellular signaling pathways in GGH3 cells.
    Pinter JH; Janovick JA; Conn PM
    Pituitary; 1999 Nov; 2(3):181-90. PubMed ID: 11081152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
    Tunn UW; Gruca D; Bacher P
    Clin Interv Aging; 2013; 8():457-64. PubMed ID: 23637525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor.
    Lee G; Ge B
    Cancer Immunol Immunother; 2010 Jul; 59(7):1011-9. PubMed ID: 20182875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth.
    Sakai M; Martinez-Arguelles DB; Patterson NH; Chaurand P; Papadopoulos V
    PLoS One; 2015; 10(3):e0120670. PubMed ID: 25811175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.